Literature DB >> 20145084

Novel FKS mutations associated with echinocandin resistance in Candida species.

Guillermo Garcia-Effron1, Daniel Joseph Chua, Jon Rupert Tomada, Joseph DiPersio, David S Perlin, Mahmoud Ghannoum, Hector Bonilla.   

Abstract

We studied three clinical isolates of Candida spp. (one C. tropicalis isolate and two C. glabrata isolates) from patients with invasive candidiasis. The first isolate emerged during echinocandin treatment, while the others emerged after the same treatment. These strains harbored an amino acid substitution in Fksp never linked before with reduced echinocandin susceptibility in C. tropicalis or in C. glabrata. The molecular mechanism of reduced susceptibility was confirmed using a 1,3-beta-D-glucan synthase inhibition assay.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20145084      PMCID： PMC2863628          DOI： 10.1128/AAC.00998-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  24 in total

1.  Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature.

Authors:  René Pelletier; Isabelle Alarie; Réal Lagacé; Thomas J Walsh
Journal:  Med Mycol       Date:  2005-09       Impact factor: 4.076

2.  Inhibition of Candida parapsilosis mitochondrial respiratory pathways enhances susceptibility to caspofungin.

Authors:  Georgios Chamilos; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

3.  Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.

Authors:  S Park; R Kelly; J Nielsen Kahn; J Robles; M-J Hsu; E Register; W Li; V Vyas; H Fan; G Abruzzo; A Flattery; C Gill; G Chrebet; S A Parent; M Kurtz; H Teppler; C M Douglas; D S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

4.  Risk Factors for Candida tropicalis fungemia in patients with cancer.

Authors:  D P Kontoyiannis; I Vaziri; H A Hanna; M Boktour; J Thornby; R Hachem; G P Bodey; I I Raad
Journal:  Clin Infect Dis       Date:  2001-09-24       Impact factor: 9.079

5.  Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints.

Authors:  Guillermo Garcia-Effron; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

6.  A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis.

Authors:  David S Krause; A E Simjee; Christo van Rensburg; Johann Viljoen; Thomas J Walsh; Beth P Goldstein; Michele Wible; Timothy Henkel
Journal:  Clin Infect Dis       Date:  2004-08-27       Impact factor: 9.079

7.  Comparison of caspofungin and amphotericin B for invasive candidiasis.

Authors:  Jorge Mora-Duarte; Robert Betts; Coleman Rotstein; Arnaldo Lopes Colombo; Luis Thompson-Moya; Juanita Smietana; Robert Lupinacci; Carole Sable; Nicholas Kartsonis; John Perfect
Journal:  N Engl J Med       Date:  2002-12-19       Impact factor: 91.245

8.  Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis.

Authors:  Michel Laverdière; Richard G Lalonde; Jean-Guy Baril; Donald C Sheppard; Steven Park; David S Perlin
Journal:  J Antimicrob Chemother       Date:  2006-02-07       Impact factor: 5.790

9.  Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis.

Authors:  Steve Hernandez; José L López-Ribot; Laura K Najvar; Dora I McCarthy; Rosie Bocanegra; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

10.  The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-beta-D-glucan synthase.

Authors:  C M Douglas; F Foor; J A Marrinan; N Morin; J B Nielsen; A M Dahl; P Mazur; W Baginsky; W Li; M el-Sherbeini
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205
View more
  48 in total

1.  Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.

Authors:  M A Pfaller; M Castanheira; S R Lockhart; A M Ahlquist; S A Messer; R N Jones
Journal:  J Clin Microbiol       Date:  2012-01-25       Impact factor: 5.948

2.  Development of echinocandin resistance in Clavispora lusitaniae during caspofungin treatment.

Authors:  Marie Desnos-Ollivier; Olivier Moquet; Taieb Chouaki; Anne-Marie Guérin; Françoise Dromer
Journal:  J Clin Microbiol       Date:  2011-04-13       Impact factor: 5.948

3.  Use of anidulafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 4,290 clinical isolates of Candida by using CLSI methods and interpretive criteria.

Authors:  Michael A Pfaller; Daniel J Diekema; Ronald N Jones; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2014-06-20       Impact factor: 5.948

4.  Implication of Candida parapsilosis FKS1 and FKS2 mutations in reduced echinocandin susceptibility.

Authors:  M Martí-Carrizosa; F Sánchez-Reus; F March; E Cantón; P Coll
Journal:  Antimicrob Agents Chemother       Date:  2015-03-16       Impact factor: 5.191

5.  Etest and Sensititre YeastOne Susceptibility Testing of Echinocandins against Candida Species from a Single Center in Austria.

Authors:  Maria Aigner; Thomas Erbeznik; Martin Gschwentner; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

6.  Stepwise development of a homozygous S80P substitution in Fks1p, conferring echinocandin resistance in Candida tropicalis.

Authors:  Rasmus Hare Jensen; Helle Krogh Johansen; Maiken Cavling Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2012-10-22       Impact factor: 5.191

7.  Breakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin.

Authors:  Fernando César Bizerra; Cristina Jimenez-Ortigosa; Ana Carolina R Souza; Giovanni Luis Breda; Flávio Queiroz-Telles; David S Perlin; Arnaldo L Colombo
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

8.  CRS-MIS in Candida glabrata: sphingolipids modulate echinocandin-Fks interaction.

Authors:  Kelley R Healey; Santosh K Katiyar; Shriya Raj; Thomas D Edlind
Journal:  Mol Microbiol       Date:  2012-08-22       Impact factor: 3.501

9.  Fungal echinocandin resistance.

Authors:  Carol A Munro
Journal:  F1000 Biol Rep       Date:  2010-09-08

10.  Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.

Authors:  Barbara D Alexander; Melissa D Johnson; Christopher D Pfeiffer; Cristina Jiménez-Ortigosa; Jelena Catania; Rachel Booker; Mariana Castanheira; Shawn A Messer; David S Perlin; Michael A Pfaller
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.